1.Klein BE: Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007, 14(4):179–183.
2.Castillo J, Aleman I, Rush SW, Rush RB: Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval Variation. American journal of ophthalmology 2017, 183:1–10.
3.Newman DK: Surgical management of the late complications of proliferative diabetic retinopathy. Eye (London, England) 2010, 24(3):441–449.
4.Spaide RF, Fisher YL: Intravitreal bevacizumab (Avastin) treatment of proliferative diabetic retinopathy complicated by vitreous hemorrhage. Retina (Philadelphia, Pa) 2006, 26(3):275–278.
5.Rizzo S, Genovesi-Ebert F, Di Bartolo E, Vento A, Miniaci S, Williams G: Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR). Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2008, 246(6):837–842.
6.di Lauro R, De Ruggiero P, di Lauro R, di Lauro MT, Romano MR: Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathy. Graefe’s archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 2010, 248(6):785–791.
7.Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA ophthalmology 2013, 131(3):283–293.
8.Martinez-Zapata MJ, Marti-Carvajal AJ, Sola I, Pijoan JI, Buil-Calvo JA, Cordero JA, Evans JR: Anti-vascular endothelial growth factor for proliferative diabetic retinopathy. Cochrane Database Syst Rev 2014(11):CD008721.
9.Sousa DC, Leal I, Costa J, Vaz-Carneiro A: [Analysis of the Cochrane Review: Anti-vascular Endothelial Growth Factor for Prevention of Postoperative Vitreous Cavity Hemorrhage after Vitrectomy for Proliferative Diabetic Retinopathy. Cochrane Database Syst Rev. 2015;8:CD008214.]. Acta Med Port 2017, 30(7–8):513–516.
10.Zhao LQ, Zhu H, Zhao PQ, Hu YQ: A systematic review and meta-analysis of clinical outcomes of vitrectomy with or without intravitreal bevacizumab pretreatment for severe diabetic retinopathy. Br J Ophthalmol 2011, 95(9):1216–1222.
11.Arevalo JF, Wu L, Sanchez JG, Maia M, Saravia MJ, Fernandez CF, Evans T: Intravitreal bevacizumab (Avastin) for proliferative diabetic retinopathy: 6-months follow-up. Eye (London, England) 2009, 23(1):117–123.
12.Kicova N, Bertelmann T, Irle S, Sekundo W, Mennel S: Evaluation of a posterior vitreous detachment: a comparison of biomicroscopy, B-scan ultrasonography and optical coherence tomography to surgical findings with chromodissection. Acta ophthalmologica 2012, 90(4):e264–268.
13.Frazer DG, Kidd MN, Johnston PB: Ghost cell glaucoma in phakic eyes. Int Ophthalmol 1987, 11(1):51–54.
14.Brooks AM, Gillies WE: Haemolytic glaucoma occurring in phakic eyes. Br J Ophthalmol 1986, 70(8):603–606.
15.Montenegro MH, Simmons RJ: Ghost cell glaucoma. Int Ophthalmol Clin 1995, 35(1):111–115.
16.Diabetic Retinopathy Clinical Research N: Randomized clinical trial evaluating intravitreal ranibizumab or saline for vitreous hemorrhage from proliferative diabetic retinopathy. JAMA ophthalmology 2013, 131(3):283–293.
17.Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Jampol LM, Melia M, Peters MA, Rauser ME: Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology 2017, 124(4):431–439.
18.Writing Committee for the Diabetic Retinopathy Clinical Research N, Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, Baker CW, Berger BB, Bressler NM et al: Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. JAMA 2015, 314(20):2137–2146.
19.Liu L, Wu WC, Yeung L, Wang NK, Kuo YH, Chao AN, Chen KJ, Chen TL, Lai CC, Hwang YS et al: Ghost cell glaucoma after intravitreal bevacizumab for postoperative vitreous hemorrhage following vitrectomy for proliferative diabetic retinopathy. Ophthalmic surgery, lasers & imaging: the official journal of the International Society for Imaging in the Eye 2010, 41(1):72–77.
20.Campbell DG, Simmons RJ, Grant WM: Ghost cells as a cause of glaucoma. American journal of ophthalmology 1976, 81(4):441–450.
21.Campbell DG, Simmons RJ, Tolentino FI, McMeel JW: Glaucoma occurring after closed vitrectomy. American journal of ophthalmology 1977, 83(1):63–69.
22.Campbell DG: Ghost cell glaucoma following trauma. Ophthalmology 1981, 88(11):1151–1158.
23.Arevalo JF, Lasave AF, Wu L, Maia M, Diaz-Llopis M, Alezzandrini AA, Brito M, Pan-American Collaborative Retina Study G: INTRAVITREAL BEVACIZUMAB FOR PROLIFERATIVE DIABETIC RETINOPATHY: Results From the Pan-American Collaborative Retina Study Group (PACORES) at 24 Months of Follow-up. Retina (Philadelphia, Pa) 2017, 37(2):334–343.
24.Farahvash MS, Majidi AR, Roohipoor R, Ghassemi F: Preoperative injection of intravitreal bevacizumab in dense diabetic vitreous hemorrhage. Retina (Philadelphia, Pa) 2011, 31(7):1254–1260.
25.Bressler SB, Beaulieu WT, Glassman AR, Gross JG, Jampol LM, Melia M, Peters MA, Rauser ME, Diabetic Retinopathy Clinical Research N: Factors Associated with Worsening Proliferative Diabetic Retinopathy in Eyes Treated with Panretinal Photocoagulation or Ranibizumab. Ophthalmology 2017, 124(4):431–439.
26.Abu el-Asrar AM, al-Obeidan SA: Pars plana vitrectomy in the management of ghost cell glaucoma. Int Ophthalmol 1995, 19(2):121–124.